Personalis secured Medicare coverage for its NeXT Personal MRD assay for surveillance in stages I–III non‑small cell lung cancer, citing TRACERx consortium evidence and Nature Medicine publications to support clinical validity. The CMS decision broadens access and strengthens the commercial case for whole‑genome MRD surveillance. VolitionRx struck a nonexclusive distribution deal with Medical & Biological Laboratories to offer its Nu.Q Discover epigenetic assays in Japan while disclosing noncompliance notices from the NYSE American that could lead to delisting. The moves reflect divergent trajectories in diagnostics: reimbursement and clinical adoption versus commercial and listing challenges.